HYBRID EVENT: Join us in person in Boston, Massachusetts, USA or attend virtually from anywhere.
13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Brain Injury and Behavioral Neuroscience
Brain Injury and Behavioral Neuroscience
Brain Injury:
It is the destruction or declension of brain cells. Brain injuries occur due to a large range of internal and external factors. In common, brain injury refers to consequential, undiscriminating trauma-induced destruction, while neurotoxicity typically mentions selective, chemically produced neuron injury.
- Traumatic brain injury (TBI)
- Acquired brain injury
Behavioral Neuroscience:
Behavioral neuroscience, also called as biological psychology, biopsychology, or psychobiology, is the implementation of the principles of biology to the study of physiological, genetic, and developmental mechanisms of behavior in humans and other animals.
- Sensation and perception.
- Motivated behavior (hunger, thirst, sex)
- Control of movement.
- Learning and memory.
- Sleep and biological rhythms.
- Emotion.
Committee Members
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States INBC 2026 Speakers
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States